Earnings Feed
Start Free
Home/Filings/4/0001610717-23-000011
4//SEC Filing

DEMANE MICHAEL F 4

Accession 0001610717-23-000011

CIK 0001444380other
View on SEC.govCompany Profile

Filed

Apr 13, 8:00 PM ET

Accepted

Apr 14, 4:22 PM ET

Size

9.8 KB

Accession

0001610717-23-000011

Insider Transaction Report

Form 4
Period: 2023-04-12
NEVRO CORPNVRO
DEMANE MICHAEL F
DirectorChief Executive Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2023-04-12$18.00/sh+80,291$1,445,238→ 101,018 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2023-04-12−80,291→ 0 total
    Exercise: $18.00Exp: 2024-11-05→ Common Stock (80,291 underlying)
Holdings

  • Common Stock

    (indirect: See footnote)
    164,344

  • Common Stock

    (indirect: See footnote)
    91,225

  • Common Stock

    (indirect: See footnote)
    82,541

  • Common Stock

    (indirect: See footnote)
    18,266
Footnotes (6)
  • [F1]Includes 4,155 restricted stock units.
  • [F2]Shares held by Catherine Q. DeMane Trustee, Michael F. DeMane 2012 Irrevocable Trust U/A/D July 26, 2012.
  • [F3]Shares held by Catherine Q. DeMane Trustee, Michael F. DeMane 2017 Family SLAT Trust U/A/D May 22, 2017.
  • [F4]Shares held by Michael F. DeMane & Catherine Q. DeMane, Trustees, Michael F. DeMane Revocable Trust U/A 10/07/2011.
  • [F5]Shares held by Michael F. DeMane, Trustee, Michael F. DeMane 2021 Retained Annuity Trust U/A 08/13/2021.
  • [F6]The shares subject to the option are fully vested and exercisable.

Documents

1 file

Issuer

NEVRO CORP

CIK 0001444380

→
Entity typeother

Related Parties

1
  • filerCIK 0001174533

Filing Metadata

Form type
4
Filed
Apr 13, 8:00 PM ET
Accepted
Apr 14, 4:22 PM ET
Size
9.8 KB
View on SEC.gov